IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it received notification from the European Patent Office (the "EPO") of an intention to grant a patent for IceCure's application entitled "Cryogen Pump". When issued, the patent will include protection for IceCure's proprietary cryogenic pump, with features that will enable IceCure's next generation of cryoablation systems. The patent will be in effect until 2041.
The novel cryogenic pump that IceCure has developed is submersible in liquid nitrogen and works in a closed circuit. In addition, this cryogenic pump is designed to be used for multiple procedures or long-term duration procedures without the need to refill liquid nitrogen. Moreover, this pump enables temperature control of the cryoprobe, as well as the use of a wider range of cryoprobes and catheters and, in addition, improves the cooling rate during a procedure.
https://finance.yahoo.com/news/icecure-medical-receives-notice-intention-130000404.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.